Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Key facts

Sponsor

Imugene Limited

Principal Investigator

John Byon, MD, PhD, M.D., PhD

Imugene Limited

Intervention

Azer-cel(biological)

Enrollment

135 enrolled

Eligibility

18 years · All sexes

Timeline

2019 – 2027

Study locations (23)

• Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
• City of Hope, Duarte, California, United States
• H. Lee Moffitt Cancer Center, Tampa, Florida, United States
• Winship Cancer Institute Emory University, Atlanta, Georgia, United States
• Northside Hospital Cancer Institute, Atlanta, Georgia, United States
• University of Maryland, Baltimore, Maryland, United States
• Tufts Medical Center, Boston, Massachusetts, United States
• Dana-Farber Cancer Institute, Boston, Massachusetts, United States
• Barbara Ann Karmanos Cancer Institute (Wayne State University), Detroit, Michigan, United States
• University of Minnesota, Minneapolis, Minnesota, United States
• Weill Cornell Medical College - NY Presbyterian Hospital, New York, New York, United States
• Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, New York, United States
• Duke University, Durham, North Carolina, United States
• Ohio State University, Columbus, Ohio, United States
• Lifespan Cancer Institute at Rhode Island Hospital, Providence, Rhode Island, United States
• +8 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07194980
  Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Fred Hutchinson Cancer Center
• RECRUITINGEARLY PHASE1NCT07428707
  Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
  National Heart, Lung, and Blood Institute (NHLBI)
• RECRUITINGPHASE4NCT07218341
  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Eli Lilly and Company
• RECRUITINGPHASE1NCT06859008
  Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  City of Hope Medical Center
• RECRUITINGPHASE2NCT07271667
  A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
  Curis, Inc.
• RECRUITINGPHASE2NCT07014917
  Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
  Zulfa Omer
• RECRUITINGPHASE2NCT06958705
  Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGPHASE1, PHASE2NCT07052695
  Mosunetuzumab for CLL MRD Clearance
  Inhye Ahn

See all trials for B-cell chronic lymphocytic leukemia →